17 cases of advanced non-small cell lung cancer treated with paclitaxel liposome plus nedaplatin  

紫杉醇脂质体联合奈达铂治疗晚期非小细胞肺癌17例(英文)

作　　者：Tao Suo Wei Ge Jinzhong Zhang Yongfa Zheng Shunxiang Luo 

机构地区：[1]Department of Oncology,Renmin Hospital of Wuhan University,Wuhan 430060,China

出　　处：《The Chinese-German Journal of Clinical Oncology》2012年第4期196-198,共3页中德临床肿瘤学杂志（英文版）

摘　　要：Objective： The aim of this study was to evaluate the recent efficacy and adverse reactions of paclitaxel liposome plus nedaplatin in the treatment of advanced non-small cell lung cancer （NSCLC）. Methods： Seventeen cases of NSCLC treated with paclitaxel liposome and nedaplatin for 2 to 6 cycles, by infusing paclitaxel liposome 135 mg/m^2 for 3 h on d 1 and nedaplatin 80 mg/m^2 as infusion on d2. Results： Among 17 patients being evaluated for response to treatment, 1 achieved complete response （CR）, 4 achieved partial response （PR）, 3 achieved stable disease （SD）, 9 achieved progress disease （PD）. The main adverse reaction was haematological toxicities, especially leukopenia and thrombocytopenia. The non-hae- matological toxicities included nausea, vomiting, mild hepatic dysfunction, alopecia and so on. Conclusion： Paclitaxel lipo- some plus nedaplatin was effective and well tolerated for treating patients with advanced NSCLCo

关 键 词：paclitaxel liposome NEDAPLATIN non-small cell lung cancer （NSCLC） 

分 类 号：S852.43[农业科学—基础兽医学] TQ460.4[农业科学—兽医学]